Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $5.2 million.

  • Pulse Biosciences' Accumulated Expenses rose 3616.85% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 3616.85%. This contributed to the annual value of $7.0 million for FY2024, which is 8424.23% up from last year.
  • As of Q3 2025, Pulse Biosciences' Accumulated Expenses stood at $5.2 million, which was up 3616.85% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Pulse Biosciences' Accumulated Expenses registered a high of $7.0 million during Q4 2024, and its lowest value of $2.3 million during Q1 2024.
  • In the last 5 years, Pulse Biosciences' Accumulated Expenses had a median value of $4.0 million in 2022 and averaged $4.1 million.
  • As far as peak fluctuations go, Pulse Biosciences' Accumulated Expenses skyrocketed by 17122.16% in 2021, and later crashed by 4021.44% in 2023.
  • Quarter analysis of 5 years shows Pulse Biosciences' Accumulated Expenses stood at $3.8 million in 2021, then crashed by 31.96% to $2.6 million in 2022, then surged by 46.97% to $3.8 million in 2023, then soared by 84.24% to $7.0 million in 2024, then dropped by 25.96% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $4.8 million for Q2 2025, and $4.0 million during Q1 2025.